IL264924A - - Google Patents

Info

Publication number
IL264924A
IL264924A IL26492419A IL26492419A IL264924A IL 264924 A IL264924 A IL 264924A IL 26492419 A IL26492419 A IL 26492419A IL 26492419 A IL26492419 A IL 26492419A IL 264924 A IL264924 A IL 264924A
Authority
IL
Israel
Application number
IL26492419A
Other languages
English (en)
Other versions
IL264924B1 (en
IL264924B2 (en
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of IL264924A publication Critical patent/IL264924A/en
Publication of IL264924B1 publication Critical patent/IL264924B1/en
Publication of IL264924B2 publication Critical patent/IL264924B2/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL264924A 2016-08-31 2017-08-24 4–4–TRIFLUORO–N–[(1S)–2–[[(7S–5–(2–HYDROXYETHYL)–6–OXO–7H–PYRIDO[2,3–D][3]BENZAZEPIN–7–YL [AMINO]–1–METHYL–2–OXO–ETHYL]BUTANAMIDE or a salt or hydrate thereof for use in the treatment of solid cancer IL264924B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662381911P 2016-08-31 2016-08-31
PCT/US2017/048308 WO2018044662A1 (en) 2016-08-31 2017-08-24 Dosage regimen for treatment of solid tumors

Publications (3)

Publication Number Publication Date
IL264924A true IL264924A (https=) 2019-04-30
IL264924B1 IL264924B1 (en) 2023-09-01
IL264924B2 IL264924B2 (en) 2024-01-01

Family

ID=59772787

Family Applications (2)

Application Number Title Priority Date Filing Date
IL264924A IL264924B2 (en) 2016-08-31 2017-08-24 4–4–TRIFLUORO–N–[(1S)–2–[[(7S–5–(2–HYDROXYETHYL)–6–OXO–7H–PYRIDO[2,3–D][3]BENZAZEPIN–7–YL [AMINO]–1–METHYL–2–OXO–ETHYL]BUTANAMIDE or a salt or hydrate thereof for use in the treatment of solid cancer
IL305136A IL305136A (en) 2016-08-31 2017-08-24 Dosage regimen for the treatment of solid tumors

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL305136A IL305136A (en) 2016-08-31 2017-08-24 Dosage regimen for the treatment of solid tumors

Country Status (14)

Country Link
US (1) US20190209581A1 (https=)
EP (1) EP3506905B1 (https=)
JP (2) JP2019526632A (https=)
KR (1) KR102512899B1 (https=)
CN (2) CN109562114A (https=)
AU (1) AU2017321011B2 (https=)
BR (1) BR112019002461A2 (https=)
CA (1) CA3035616A1 (https=)
ES (1) ES2977556T3 (https=)
IL (2) IL264924B2 (https=)
MA (1) MA46086A (https=)
MX (1) MX387397B (https=)
SG (2) SG11201901325UA (https=)
WO (1) WO2018044662A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI609687B (zh) 2015-04-14 2018-01-01 美國禮來大藥廠 平滑肌肉瘤之標靶性治療
ES2881801T3 (es) 2016-04-12 2021-11-30 Lilly Co Eli Terapia de combinación con inhibidores de Notch y CDK4/6 para su uso en el tratamiento de cáncer de pulmón
WO2017180385A1 (en) 2016-04-12 2017-10-19 Eli Lilly And Company Combination therapy with notch and pi3k/mtor inhibitors for use in treating cancer
MA45025A (fr) 2016-05-20 2019-03-27 Lilly Co Eli Traitement d'association utilisant des inhibiteurs de notch et de pd-1 ou pd-l1
US11376259B2 (en) 2016-10-12 2022-07-05 Eli Lilly And Company Targeted treatment of mature T-cell lymphoma
IL268349B2 (en) 2017-02-17 2024-08-01 Hutchinson Fred Cancer Res Combination therapies for treatment of bcma-related cancers and autoimmune disorders
SG11202003427XA (en) 2017-11-06 2020-05-28 Juno Therapeutics Inc Combination of a cell therapy and a gamma secretase inhibitor

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US46206A (en) 1865-02-07 Improved vessel for holding petroleum
WO2008112249A1 (en) * 2007-03-13 2008-09-18 Trustees Of Columbia University In The City Of New York Synergistic interaction of notch-1 inhibitors with glucocorticoids
EP2214679B1 (en) * 2007-11-13 2019-03-27 Meritage Pharma, Inc. Corticosteroid compositions
AR087107A1 (es) 2011-07-27 2014-02-12 Lilly Co Eli Compuesto inhibidor de la señalizacion de la trayectoria notch
CA2952315A1 (en) * 2014-07-11 2016-01-14 Genentech, Inc. Notch pathway inhibition
TWI609687B (zh) * 2015-04-14 2018-01-01 美國禮來大藥廠 平滑肌肉瘤之標靶性治療

Also Published As

Publication number Publication date
AU2017321011A1 (en) 2019-02-21
SG11201901325UA (en) 2019-03-28
BR112019002461A2 (pt) 2019-05-14
IL264924B1 (en) 2023-09-01
EP3506905A1 (en) 2019-07-10
EP3506905B1 (en) 2024-03-20
CA3035616A1 (en) 2018-03-08
IL264924B2 (en) 2024-01-01
KR20190042591A (ko) 2019-04-24
MA46086A (fr) 2019-07-10
JP2019526632A (ja) 2019-09-19
WO2018044662A1 (en) 2018-03-08
JP2023052108A (ja) 2023-04-11
ES2977556T3 (es) 2024-08-26
KR102512899B1 (ko) 2023-03-23
US20190209581A1 (en) 2019-07-11
MX387397B (es) 2025-03-18
SG10202107832UA (en) 2021-09-29
AU2017321011B2 (en) 2023-08-03
IL305136A (en) 2023-10-01
CN116473978A (zh) 2023-07-25
MX2019002066A (es) 2019-06-03
CN109562114A (zh) 2019-04-02

Similar Documents

Publication Publication Date Title
BR112019001695A2 (https=)
BR122021013712A2 (https=)
BR112019002665A2 (https=)
IL264924A (https=)
BR112019001429A2 (https=)
BR112019009192A2 (https=)
BR112017026947A2 (https=)
BR112019009269A2 (https=)
BR112019003108A2 (https=)
BR102016025845A2 (https=)
BR202016025584U2 (https=)
BR202016018234U2 (https=)
BR102016014616A2 (https=)
CN303538754S (https=)
CN303668479S (https=)
CN303589815S (https=)
CN303586825S (https=)
CN303538530S (https=)
CN303594891S (https=)
CN303595571S (https=)
CN303605892S (https=)
CN303617791S (https=)
CN303560039S (https=)
CN303559987S (https=)
CN303538699S (https=)